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doi:10.1Objective: Postoperative atrial fibrillation is the most common complication after cardiac surgery. A variety of
postoperative atrial fibrillation risk factors have been reported, but study results have been inconsistent or con-
tradictory, particularly in patients with preexisting atrial fibrillation. The incidence of postoperative atrial fibril-
lation was evaluated in a group of 10,390 patients undergoing cardiac surgery among a comprehensive range of
risk factors to identify reliable predictors of postoperative atrial fibrillation.
Methods: This 20-year retrospective study examined the relationship between postoperative atrial fibrillation and
demographic factors, preoperative health conditions and medications, operative procedures, and postoperative
complications. Multivariate logistic regression models were used to evaluate potential predictors of postoperative
atrial fibrillation.
Results: Increasing age, mitral valve surgery (odds ratio ¼ 1.91), left ventricular aneurysm repair (odds
ratio ¼ 1.57), aortic valve surgery (odds ratio ¼ 1.52), race (Caucasian) (odds ratio ¼ 1.51), use of cardioplegia
(odds ratio¼ 1.36), use of an intraaortic balloon pump (odds ratio¼ 1.28), previous congestive heart failure (odds
ratio ¼ 1.28), and hypertension (odds ratio ¼ 1.15) were significantly associated with postoperative atrial fibril-
lation. The non-linear relationship between age and postoperative atrial fibrillation revealed the acceleration of
postoperative atrial fibrillation risk in patients aged 55 years or more. In patients undergoing coronary artery by-
pass grafting, increasing age and previous congestive heart failure were the only factors associated with a higher
risk of postoperative atrial fibrillation. There was no trend in incidence of postoperative atrial fibrillation over
time. No protective factors against postoperative atrial fibrillation were detected, including commonly prescribed
categories of medications.
Conclusions: The persistence of the problem of postoperative atrial fibrillation and the modest predictability us-
ing common risk factors suggest that limited progress has been made in understanding its cause and treatment.
(J Thorac Cardiovasc Surg 2011;141:559-70)Postoperative atrial fibrillation (POAF) is the most common
complication after cardiac surgery. POAF occurs early in
the recovery period after surgery, is associated with an in-
creased incidence ofmortality and other morbidities, and con-
tributes significantly to longer hospital stays and higher cost
of care.1-4 The reported incidence ranges from 11% to 50%,
depending on the patient cohort evaluated.1 Because the un-
derlying pathophysiologic mechanisms responsible for
POAF remain largely undetermined, the use of statistical
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Mthe most practical approach to POAF prevention and evalua-
tion of potential treatments. Various risk factors for POAF
have been reported; however, study results have been incon-
sistent or contradictory, possibly because of small study
sample sizes, limited control of confounding factors, and
interference from preexisting atrial fibrillation. Only increas-
ing age has been a consistently reported independent risk fac-
tor for POAF.2,4,5 Evaluating predictors of POAF across
studies has also been difficult because the characteristics of
study samples are rarely replicable, and confounding risk
factors differ between studies. This may lead to biased or
limited generalization to the overall patient population
undergoing cardiac surgery.
In the 20-year period from 1986 to 2005, 14,960 cardiac
surgical procedures were performed at Barnes-Jewish Hos-
pital. This large patient population provided a unique oppor-
tunity for a comprehensive study of POAF. The primary
objectives of this 20-year retrospective study were to evalu-
ate trends in the incidence of POAF over time and potential
predictors of POAF. Various cardiovascular medications are
frequently administered to patients as prophylaxis against
postoperative arrhythmias. However, the data supporting
these practices have been inconsistent. This study alsordiovascular Surgery c Volume 141, Number 2 559
Abbreviations and Acronyms
AUC ¼ area under the receiver operating
characteristic curve
CABG ¼ coronary artery bypass grafting
CHF ¼ congestive heart failure
MLR ¼ multivariate logistic regression
OR ¼ odds ratio
POAF ¼ postoperative atrial fibrillation
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Msought to evaluate the effects of various cardiovascular and
non-cardiovascular medications on the incidence of POAF
when administered preoperatively. An additional objective
of the study was to evaluate the association between
POAF and postoperative outcomes.MATERIALS AND METHODS
Study Population
From January 1, 1986, to December 30, 2005, 14,960 cardiac surgical
procedures were performed at Barnes-Jewish Hospital. Of these cases,
10,390 patients without preexisting atrial arrhythmias (atrial fibrillation,
atrial flutter, and paroxysmal atrial tachycardia) were selected for inclusion
in this study. Appropriate institutional review board approval was obtained.
Patient ages ranged from 12 to 94 years (median ¼ 64 years), with
a mean of 62.3 12.9 years. Men comprised 65% of the study population,
and more than 87% of the patients were Caucasian. Approximately 79% of
the procedures were elective, with the remaining being emergency (11%) or
urgent (10%) operations. After surgery, all patients received continuous
24-hour telemetry with arrhythmia-detection algorithms during their entire
hospital stay.
Measures
Patient information, including demographics, preoperative medical
history, and peri- and postoperative data, was extracted from individual med-
ical records. The onset of POAF was the dichotomous dependent variable in
the analyses. POAF was diagnosed as atrial fibrillation/flutter occurring
during the postoperative recovery period before hospital discharge and requir-
ing treatment. This did not include transient, nonsustained arrhythmias, or
arrhythmias treated only with oxygen or potassium supplementation. Fifty-
one independent variables, or potential predictors, were organized into 4
groups: (1) demographics, (2) preoperative medical history, (3) preoperative
medications, and (4) intraoperative procedures (type of surgery performed
and any other procedures or devices used).A complete list of independent var-
iables is included in Table 1. It should be noted that, although one of the aims
of this studywas to evaluate the efficacy of variousmedications as POAF pro-
phylaxis, the reason for administering a particular medication at the time may
have been POAF prophylaxis, or a different reason altogether, such as an
acute or chronic condition.
Information on postoperative complications, such as stroke, length of
hospital stay after surgery, and mortality, was also collected (listed in
Table 2) to look for any association with new-onset POAF.
Analysis
Descriptive statistics, chi-square tests, Mann–Whitney Wilcoxon tests,
and odds ratios (ORs) were applied to describe the study population and
the univariate relationships between individual variables and POAF.
Multivariate logistic regression (MLR) models were used to predict the
onset of POAF, with a stepwise selection of significant predictors. Because560 The Journal of Thoracic and Cardiovascular Surgof the large size of the study population, a stringent selection criterion of a P
value of .05 or less was used for entering and removing independent vari-
ables in the model. In a large-scale database with more than 50 potential pre-
dictors, the presence of missing data is inevitable; its cumulative impact on
multivariate analyses due to case-wise deletion often overwhelmingly re-
duces the number of patients available for analysis. To minimize this im-
pact, the MLR incorporated only those independent variables that were
significant at the P level of .10 or less after univariate analysis. The onset
of POAF was predicted by MLR for all patients undergoing cardiac surgery
(model 1) and for patients who only underwent coronary artery bypass graft-
ing (CABG) (model 2). Because of case-wise deletion caused by missing
values, model 1 had only 5075 patients available for analysis, which yielded
10 significant predictors of POAF. By using only these 10 significant pre-
dictors in a third MLR model (model 3), we were able to retain more cases
(N¼ 10,371) while verifying the stability of these 10 predictors when reap-
plied to the entire study population (all patients undergoing cardiac surgery).
Information on preoperative warfarin use was missing for 5354 patients.
To avoid case-wise deletion of these cases in the comprehensive analysis,
this variable was excluded from the MLR models. In a preliminary MLR
model, warfarin use was coded as ‘‘yes,’’ ‘‘no,’’ or ‘‘unknown’’ to retain
missing cases in the analysis. This showed that preoperative warfarin use
was not significantly different from no use in terms of predicting POAF.
Therefore, it was safe to exclude this variable from the final analyses with
minimal risk of losing a predictor of POAF.
Analyses were conducted using SAS software, version 9.1.6 Three statis-
tics were calculated to evaluate the appropriateness of the models: the
Hosmer–Lemeshow statistic testing the goodness of fit between the observed
and the predicted occurrence of POAF; the likelihood ratio testing the global
significance of the selected predictors of POAF; and the area under the re-
ceiver operating characteristic curve (AUC) depicting the adequacy of the
model for detecting the onset of POAF.
RESULTS
The average incidence of POAF was found to be 30%
(range, 25%–36%) for the study population over the 20-
year period (Figure 1). There was no significant effect of
year of surgery on POAF (P ¼ .17). The incidence of
POAF ranged from 14% to 47% across 4 different age
groups (Table 1). The odds of having POAF in patients
aged 72 years or more were 5.6 times (OR ¼ 5.57) greater
than in patients aged 12 to 54 years. Although increasing
age has consistently been associated with a higher incidence
of POAF, the relationship between age and POAF is nonlin-
ear. Figure 2 illustrates that beyond age 55 years, for example,
the estimated probability of having POAF increases more
steeply, from 20% to 80%, whereas the probability increases
more slowly (up to 20%) for patients aged less than 55 years.
Table 1 presents the results of univariate analysis of the as-
sociation between individual variables and new-onset POAF.
ORs and their 95% confidence intervals are presented for
those variables that were significantly related to POAF. Cau-
casian patients had 59% greater odds (OR ¼ 1.59) of having
POAF compared with patients of African-American descent.
The likelihoods of developing POAF in patients with a preop-
erative history of congestive heart failure (CHF), chronic
obstructive pulmonary disease, hypertension, or aortic valve
stenosis were approximately 1.6, 1.4, 1.3, and 1.7 times,
respectively, those in patients without such corresponding
histories. Similarly, the incidence of POAF in patientsery c February 2011
TABLE 1. Chi-square and odds ratios for univariate predictors and associates of postoperative atrial fibrillation
POAF Chi-square test Odds ratio
Variable* No, n (%) Yes, n (%) c2 P OR (95% CI)
Demographics
Quartile age group 766.57 <.0001
12  54 y 2321 (86%) 364 (14%) ref
55  63 y 1888 (75%) 624 (25%) 2.11 (1.83–2.43)
64  71 y 1646 (64%) 945 (36%) 3.66 (3.19–4.19)
72þy 1389 (53%) 1213 (47%) 5.57 (4.86–6.37)
Gender 0.33 .5650
Female 2541 (69%) 1122 (31%)
Male 4703 (70%) 2024 (30%)
Race 43.26 <.0001
African-American 921 (78%) 266 (22%) ref
Caucasian 6205 (69%) 2841 (31%) 1.59 (1.37–1.83)
Other 107 (76%) 33 (24%) 1.07 (0.71–1.61)
Preoperative medical history
Smoking history 11.60 .0007
No 2292 (67%) 1109 (33%) ref
Yes 4866 (71%) 2019 (29%) 0.86 (0.78–0.94)
Current smoker 66.53 <.0001
No 5201 (67%) 2510 (33%) ref
Yes 1956 (76%) 618 (24%) 0.65 (0.59–0.73)
COPD 29.99 <.0001
No 6431 (71%) 2676 (29%) ref
Yes 813 (63%) 470 (37%) 1.39 (1.23–1.57)
Hypertension 35.90 <.0001
No 2750 (73%) 1001 (27%) ref
Yes 4494 (68%) 2145 (32%) 1.31 (1.20–1.43)
Angina pectoris 12.30 .0021
None 2048 (69%) 923 (31%) ref
Stable 2357 (72%) 915 (28%) 0.86 (0.77–0.96)
Unstable 2839 (68%) 1308 (32%) 1.02 (0.92–1.13)
Myocardial infarction 4.29 .0384
No 3828 (71%) 1593 (29%) ref
Yes 3416 (69%) 1553 (31%) 1.09 (1.00–1.19)
CHF 94.49 <.0001
No 5365 (73%) 2034 (27%) ref
Yes 1878 (63%) 1111 (37%) 1.56 (1.43–1.71)
NYHA score for CHF 105.75 <.0001
0 3304 (74%) 1166 (26%) ref
1 20 (61%) 13 (39%) 1.84 (0.91–3.72)
2 440 (62%) 274 (38%) 1.77 (1.50–2.08)
3 687 (62%) 417 (38%) 1.72 (1.50–1.98)
4 730 (64%) 407 (36%) 1.58 (1.38–1.81)
Stroke 5.47 .0194
No 6648 (70%) 2843 (30%) ref
Yes 596 (66%) 303 (31%) 1.19 (1.03–1.37)
Peripheral vascular disease 19.44 <.0001
No 5201 (67%) 2510 (33%) ref
Yes 1956 (76%) 618 (24%) 1.29 (1.15–1.44)
Diabetes 0.93 .3343
No 5168 (70%) 2215 (30%)
Yes 2076 (69%) 931 (31%)
Renal insufficiency 9.75 .0018
No 6653 (70%) 2834 (30%) ref
Yes 576 (65%) 309 (35%) 1.26 (1.09–1.46)
(Continued)
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TABLE 1. Continued
POAF Chi-square test Odds ratio
Variable* No, n (%) Yes, n (%) c2 P OR (95% CI)
Dialysis 0.16 .6854
No 7112 (70%) 3085 (30%)
Yes 132 (68%) 61 (32%)
Aortic valve insufficiency 16.55 .0003
None/mild 5644 (69%) 2420 (31%) ref
Moderate 242 (62%) 151 (38%) 1.42 (1.15–1.75)
Severe 263 (64%) 151 (36%) 1.31 (1.06–1.60)
Mitral valve insufficiency 32.84 <.0001
None/mild 5435 (70%) 2306 (30%) ref
Moderate 548 (66%) 281 (34%) 1.21 (1.04–1.41)
Severe 537 (61%) 339 (39%) 1.49 (1.29–1.72)
Tricuspid valve insufficiency 1.73 .4214
None/mild 5824 (69%) 2600 (31%)
Moderate 215 (67%) 107 (33%)
Severe 92 (73%) 34 (27%)
Aortic valve stenosis 72.71 <.0001
No 6550 (71%) 2672 (29%) ref
Yes 663 (59%) 467 (41%) 1.73 (1.52–1.96)
Mitral valve stenosis 5.78 .0162
No 7120 (70%) 3079 (30%) ref
Yes 95 (61%) 61 (39%) 1.48 (1.07–2.05)
Tricuspid valve stenosis – –
No 7210 (70%) 3141 (30%)
Yes 2 (100%) 0 (0%)
PCI 6.38 .0116
No 6184 (71%) 2578 (29%) ref
Yes 1060 (65%) 568 (35%) 0.86 (0.76–0.97)
Previous CABG 1.47 .2258
No 6705 (70%) 2933 (30%)
Yes 539 (72%) 213 (28%)
Previous valve procedure 4.90 .0269
No 7083 (70%) 3097 (30%) ref
Yes 161 (77%) 49 (23%) 0.70 (0.50–0.96)
Previous LVA repair 0.75 .3859
No 7232 (70%) 3143 (30%)
Yes 12 (80%) 3 (20%)
Congenital defect repair 7.34 .0067
No 7191 (70%) 3137 (30%) ref
Yes 53 (85%) 9 (15%) 0.39 (0.19–0.79)
Preoperative medications
Antiarrhythmics 0.79 .3729
No 4557 (69%) 2001 (31%)
Yes 146 (67%) 73 (33%)
Beta-blockers 1.42 .2327
No 3657 (69%) 1631 (31%)
Yes 3556 (70%) 1507 (30%)
Ca2þ-channel blocker 0.14 .7119
No 4332 (69%) 1906 (31%)
Yes 435 (70%) 185 (30%)
IV nitrates 0.21 .6488
No 6633 (70%) 2876 (30%)
Yes 581 (69%) 261 (31%)
(Continued)
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TABLE 1. Continued
POAF Chi-square test Odds ratio
Variable* No, n (%) Yes, n (%) c2 P OR (95% CI)
Digitalis 3.84 .0500
No 6207 (70%) 2624 (30%) ref
Yes 557 (67%) 274 (33%) 1.16 (1.00–1.35)
Inotropic agents 0.22 .6381
No 7039 (70%) 3056 (30%)
Yes 175 (68%) 81 (32%)
ACE inhibitors 1.36 .2431
No 4235 (69%) 1868 (31%)
Yes 1639 (68%) 768 (32%)
Diuretics 22.27 <.0001
No 5203 (71%) 2099 (29%) ref
Yes 1573 (66%) 805 (34%) 1.27 (1.15–1.40)
Aspirin/Ecotrin 2.28 .1314
No 2789 (71%) 1164 (29%)
Yes 4425 (69%) 1974 (31%)
Coumadin 5.32 .0211
No 3214 (68%) 1535 (32%) ref
Yes 213 (74%) 74 (26%) 0.7 (0.55–0.95)
Anticoagulants (non-Coumadin) 2.09 .1479
No 2259 (68%) 1058 (32%)
Yes 3293 (70%) 1437 (30%)
Lipid-lowering medications 1.44 .2301
No 3238 (67%) 1571 (33%)
Yes 575 (69%) 253 (31%)
Steroids 2.42 .1196
No 7009 (70%) 3030 (30%)
Yes 205 (66%) 107 (34%)
Intraoperative procedures
Clinical status 3.07 .2153
Elective 5695 (70%) 2448 (30%)
Emergency 797 (70%) 343 (30%)
Urgent 728 (67%) 353 (33%)
Valve procedure 109.28 <.0001
No 5853 (72%) 2251 (28%) ref
Yes 1391 (61%) 895 (39%) 1.67 (1.52–1.84)
Aortic valve procedure 80.27 <.0001
No 6366 (71%) 2555 (29%) ref
Yes 878 (60%) 591 (40%) 1.68 (1.50–1.88)
Mitral valve procedure 59.07 <.0001
No 6699 (71%) 2762 (29%) ref
Yes 545 (59%) 384 (41%) 1.71 (1.49–1.96)
Tricuspid valve procedure 3.70 .0543
No 7164 (70%) 3124 (30%)
Yes 80 (78%) 22 (22%)
CABG 9.74 .0018
No 1607 (72%) 612 (28%) ref
Yes 5637 (69%) 2534 (31%) 1.18 (1.06–1.31)
CABG and valve procedure 204.05 <.0001
Neither 667 (81%) 153 (19%) ref
CABG only 5186 (71%) 2098 (29%) 1.76 (1.47–2.12)
Valve only 940 (67%) 459 (33%) 2.13 (1.73–2.62)
Both 451 (51%) 436 (49%) 4.21 (3.38–5.25)
(Continued)
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TABLE 1. Continued
POAF Chi-square test Odds ratio
Variable* No, n (%) Yes, n (%) c2 P OR (95% CI)
LVA repair 9.13 .0025
No 7124 (70%) 3066 (30%) ref
Yes 120 (60%) 80 (40%) 1.55 (1.16–2.06)
VSD repair 2.92 .0877
No 7228 (70%) 3133 (30%)
Yes 16 (55%) 13 (45%)
Ventricular assist device 0.19 .6665
No 7167 (70%) 3110 (30%)
Yes 76 (68%) 36 (32%)
Cardioplegia used 41.86 <.0001
No 805 (79%) 220 (21%) ref
Yes 6439 (69%) 2926 (31%) 1.66 (1.42–1.94)
IABP used 34.62 <.0001
No 6530 (71%) 2712 (29%) ref
Yes 714 (62%) 434 (38%) 1.46 (1.29–1.66)
Crossclamp time (min) 27.54 <.0001
0 515 (75%) 172 (25%) ref
3–49 1733 (72%) 679 (28%) 1.17 (0.97–1.42)
50–69 1638 (69%) 724 (31%) 1.32 (1.02–1.61)
70–97 1654 (69%) 740 (31%) 1.34 (1.10–1.63)
98–410 1575 (66%) 800 (34%) 1.52 (1.26–1.84)
POAF, Postoperative atrial fibrillation; OR, odds ratio; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CHF, congestive heart failure; NYHA, New York
Heart Association; CABG, coronary artery bypass graft; LVA, left ventricular aneurysm; IV, intravenous; ACE, angiotensin-converting enzyme; VSD, ventricular septal defect; PCI,
percutaneous cardiac intervention; IABP, intraaortic balloon pump. *The year when the current surgery was performed is not shown but was included in the multivariate analysis.
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Mundergoing an aortic or mitral valve procedure was approxi-
mately 1.7 times that in patients undergoing other cardiac pro-
cedures.
Twelve of the 13 types of preoperative medications in-
cluded in this study did not show a preventive effect against
POAF, contrary to what has been reported for some of these
medications in controlled trials7,8 or retrospective studies.1,9
During the 20-year period, the preoperative use of beta-
blockers increased from 36% to 59%. Despite this increased
use, the incidence of POAF did not decrease. Overall, the in-
cidence was 30% for those patients receiving beta-blockers,
versus 31% for those who were not. Likewise, the use of
angiotensin-converting enzyme inhibitors increased from
5% to 47% during the 20-year period, with no significant
reduction in POAF. Although the univariate analysis
(Table 1) showed that warfarin reduced the chance of
POAF by 30%, this effect was not significant after control-
ling for other factors in the multivariate analysis. Similarly,
patients taking digitalis or diuretics had a higher risk of
POAF (Table 1), but this effect also did not hold up in the
multivariate analysis.
Table 2 shows the co-occurrence of POAF and other
postoperative complications, as well as the association be-
tween POAF and the length of hospital stay and mortality
after cardiac procedures. POAF was positively associated
with permanent stroke, the requirement for implantation of
a permanent pacemaker, and mortality (OR ¼ 2.42,564 The Journal of Thoracic and Cardiovascular SurgOR ¼ 2.62, and OR ¼ 1.75, respectively). Among the 14
complications studied other than POAF, 13 had a positive as-
sociation with POAF (Table 2). The incidence of death from
a neurologic cause was more than doubled in patients with
POAF.
Consistentwith the results of other studies,1-3 theoccurrence
of POAF was associated with a 2-day longer hospital stay, as
evaluated in this study by the median length of stay from
surgery to discharge and a 1-day longer median length of
stay in the intensive care unit and stepdown unit after
surgery (see Table 2 for details).
Table 3 presents significant variables as independent pre-
dictors of POAF that were detected by theMLRmodels. The
goodness-of-fit, likelihood ratio, and AUC show that the
models fit the data adequately.
For all types of cardiac procedures collectively (model 1),
increasing age was strongly associated with POAF, as ex-
pected. The odds of a person aged 72þ years developing
POAF, for example, are 4.4 times those for a patient aged
less than 55 years. Over the 20-year period, the average pa-
tient age ranged from 60 to 64 years. There was no trend in
age over the study period. The average agewas 60 13 years
in 1986 and 61 14 years in 2005. New-onset POAFwas 1.5
times as likely to occur among Caucasians as among patients
of African-American or other racial/ethnic backgrounds. A
history of CHF was associated with a 40% higher risk of
developing POAF, and preexisting hypertension was relatedery c February 2011
TABLE 2. Association between new-onset postoperative atrial fibrillation and postoperative course (N ¼ 10,390)
Variable
POAF Chi-square test Odds ratio
No, n (%) Yes, n (%) c2 P OR (95% CI)
Complication
MI 8.82 .0030
No 7201 (70%) 3110 (30%) ref
Yes 43 (54%) 895 (46%) 1.94 (1.24–3.02)
Permanent pacemaker 50.10 <.0001
No 7146 (70%) 3037 (30%) ref
Yes 98 (47%) 109 (53%) 2.62 (1.99–3.45)
Low cardiac output 102.79 <.0001
No 6839 (71%) 2793 (29%) ref
Yes 405 (53%) 353 (47%) 2.13 (1.84–2.48)
Tamponade 36.58 <.0001
No 7132 (70%) 3039 (30%) ref
Yes 112 (51%) 107 (49%) 2.24 (1.71–2.93)
Operative reexploration for bleeding 35.57 <.0001
No 6943 (70%) 2928 (30%) ref
Yes 301 (58%) 218 (42%) 1.72 (1.44–2.06)
Anticoagulant complications 36.44 <.0001
No 7153 (70%) 3053 (30%) ref
Yes 91 (49%) 93 (51%) 2.39 (1.79–3.21)
Transient stroke 21.24 <.0001
No 7167 (70%) 3076 (30%) ref
Yes 77 (52%) 70 (48%) 2.12 (1.53–2.94)
Permanent stroke 56.13 <.0001
No 7105 (70%) 3004 (30%) ref
Yes 139 (49%) 142 (51%) 2.42 (1.91–3.06)
Deep sternal infection 20.54 <.0001
No 7195 (70%) 3095 (30%) ref
Yes 49 (49%) 51 (51%) 2.42 (1.63–3.59)
Superficial sternal infection 2.82 .0934
No 7075 (70%) 3055 (30%)
Yes 169 (65%) 91 (35%)
Leg infection 15.76 <.0001
No 7111 (70%) 3049 (30%) ref
Yes 133 (58%) 097 (42%) 1.70 (1.30–2.22)
Pneumonia 247.51 <.0001
No 6903 (72%) 2721 (28%) ref
Yes 341 (46%) 424 (55%) 3.15 (2.72–3.66)
Acute renal failure 116.75 <.0001
No 6957 (71%) 2855 (29%) ref
Yes 287 (50%) 291 (50%) 2.47 (2.09–2.93)
GI complications 221.27 <.0001
No 6869 (72%) 2716 (28%) ref
Yes 375 (47%) 430 (53%) 2.90 (2.51–3.35)
Length of stay in hospital (d)
Length of stay in ICU Median ¼ 2
(Q1, Q3: 1, 5)
Median ¼ 3
(Q1, Q3: 1, 8)
Z* ¼ 14.71 <.0001
Length of stay, surgery to discharge Median ¼ 7
(Q1, Q3: 5, 9)
Median ¼ 9
(Q1, Q3: 7,15)
Z ¼ 34.64 <.0001
Length of stay, stepdown unit Median ¼ 4
(Q1, Q3: 2, 6)
Median ¼ 5
(Q1, Q3: 3, 9)
Z ¼ 16.77 <.0001
Mortality
Mortality 104.58 <.0001
No 6268 (72%) 2471 (28%) ref
Yes 976 (59%) 675 (41%) 1.75 (1.57–1.96)
(Continued)
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TABLE 2. Continued
Variable
POAF Chi-square test Odds ratio
No, n (%) Yes, n (%) c2 P OR (95% CI)
30-d mortality 3.57 .0587
No 6932 (70%) 2984 (30%)
Yes 312 (66%) 162 (34%)
Cause of death: cardiac 10.34 .0014
No 6984 (70%) 2991 (30%) ref
Yes 260 (63%) 155 (37%) 1.39 (1.14–1.71)
Cause of death: neurologic 15.02 .0001
No 7192 (70%) 3098 (30%) ref
Yes 52 (52%) 48 (48%) 2.14 (1.44–3.18)
Cause of death: pulmonary 19.57 <.0001
No 7153 (70%) 3069 (30%) ref
Yes 91 (54%) 77 (46%) 1.97 (1.45–268)
Cause of death: infection 5.51 .0189
No 7194 (70%) 3110 (30%) ref
Yes 50 (58%) 36 (42%) 1.67 (1.08–2.56)
POAF, Postoperative atrial fibrillation; OR, odds ratio; CI, confidence interval;MI,myocardial infarction;GI, gastrointestinal; ICU, intensive care unit. *Mann–Whitney Wilcoxon
test.
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Mto a 15% higher risk of POAF. More important, the data
seem to indicate that undergoing certain types of cardiac pro-
cedures carries a significant risk of POAF: An aortic or mitral
valve procedure, CABG, or left ventricular aneurysm repair
introduces a 51%, 88%, 23%, and 62% higher risk of
POAF, respectively. Because of the small number of tricus-
pid valve procedures and ventricular septal defect repairs
available for analysis, this study was unable to determine
the POAF risk for these procedures. Other studies have re-
ported that the incidence of POAF is greater for combined
procedures than for isolated procedures.2 In this database,
8.5% of patients (n ¼ 887) had a combined valve and
CABG procedure. Although this combined procedure was
significant in the univariate analysis (Table 1), it was not
a significant predictor in the multivariate analysis.0
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FIGURE1. Incidence of new-onset POAF for all patients and only patients
undergoing CABG over a 20-year period. POAF, Postoperative atrial fibril-
lation; CABG, coronary artery bypass grafting.
566 The Journal of Thoracic and Cardiovascular SurgIncreasing the crossclamp time during a procedure did not
significantly increase the risk of POAF. Multivariate analy-
sis also indicated that the use of intraoperative cardioplegia
to arrest the heart and intraaortic balloon pump increased the
risk of POAF by 23% and 27%, respectively. However, the
POAF risk related to intraoperative cardioplegia may have
been affected by the heterogeneous nature of its reference
group, which included off-pump CABG (which might
have been related to less POAF), type A aortic dissection re-
pairs where circulatory arrest was used, and other surgeries,
each of which did not involve cardioplegia but carried vary-
ing risks of POAF.
Approximately 80% of the cardiac procedures involved
CABG, and more than 68% of all surgeries were lone
CABG procedures. Model 2 analyzed the lone CABG sur-
geries and revealed that increasing age and history of CHF
were the only 2 independent risk factors associated with0
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FIGURE 2. Estimated probability of POAF by age. POAF, Postoperative
atrial fibrillation; CI, confidence interval.
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TABLE 3. Predictors of new-onset postoperative atrial fibrillation and odds ratios (95% confidence interval)
Predictor
Model 1
All procedures
(N ¼ 5075)
OR (95% CI)
Model 2
CABG only
(N ¼ 3058)
OR (95% CI)
Model 3
Re-test of model 1
(N ¼ 10,371)
OR (95% CI)
Demographics
Age group
12–54 y ref ref ref
55–63 y 1.84 (1.49–2.27) 1.77 (1.33–2.36) 2.12 (1.84–2.46)
64–71 y 3.39 (2.77–4.14) 3.28 (2.50–4.31) 3.72 (3.24–4.29)
72þy 4.36 (3.59–5.29) 4.19 (3.20–5.49) 5.34 (4.64–6.14)
Race
African-American ref ref
Caucasian 1.50 (1.23–1.83) 1.51 (1.30–1.76)
Other 0.89 (0.46–1.71) 1.12 (0.72–1.73)
Preoperative medical history
CHF
No ref ref ref
Yes 1.39 (1.22–1.58) 1.46 (1.24–1.72) 1.28 (1.16–1.42)
Hypertension
No ref ref
Yes 1.15 (1.00–1.32) 1.15 (1.04–1.26)
Intraoperative conditions
Aortic valve procedure
No ref –* ref
Yes 1.51 (1.26–1.81) 1.52 (1.34–1.72)
Mitral valve procedure
No ref – ref
Yes 1.88 (1.54–2.30) 1.91 (1.64–2.23)
CABG
No ref –
Yes 1.23 (1.03–1.47)
LVA repair
No ref – ref
Yes 1.62 (1.12–2.34) 1.57 (1.15–2.13)
Cardioplegia used
No ref ref
Yes 1.27 (1.02–1.47) 1.36 (1.15–1.60)
IABP used
No ref ref
Yes 1.24 (1.04–1.49) 1.28 (1.11–1.46)
Goodness-of-fit: c2 (df); P
Likelihood ratio: c2 (df); P
7.44 (8); P ¼ .4901
510.14 (13); P< .0001
1.77 (6); P ¼ .9399
186.55 (4); P<.0001
9.83 (8); P ¼ .2770
1054.41 (12); P< .0001
AUC .69 .65 .70
CI, Confidence interval; OR, odds ratio; CHF, congestive heart failure; CABG, coronary artery bypass graft; LVA, left ventricular aneurysm; IABP, intraaortic balloon pump;
AUC, area under the curve. *Not applicable for analysis.
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Ma higher probability of POAF. Patients with a history of CHF
were 46% more likely to have POAF. In contrast with the
results of model 1, being of Caucasian descent or having pre-
existing hypertension did not increase the risk of POAF after
lone CABG procedures.
Model 3 imposed the 10 variables as predictors on a larger
number of patients (N¼ 10,371) and confirmed the stability
of model 1’s results. CABG was the only variable (in model
1) that turned out to be nonsignificant in the re-test (model 3).
During the 20-year period examined, the percentage ofThe Journal of Thoracic and Capatients with CHF increased from 25% to 40% (Figure 3).
The percentage of patients with hypertension increased
from 52% to 72%. The use of cardioplegia decreased
from 96% to 82%. The percentage of patients undergoing
CABG procedures decreased from 90% to 55%, whereas
the percentage of mitral valve and aortic valve procedures in-
creased from 4% and 9% to 20% and 26%, respectively.
The Hosmer–Lemeshow test and AUC showed that both
models 1 and 3 were similar in their goodness of fit and ad-
equate discriminative power (AUC ¼ 0.70). Even withrdiovascular Surgery c Volume 141, Number 2 567
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FIGURE 3. A, Trends in type of operation. B, Trend in CHF. C, Trend in hypertension. D, Trend in the use of cardioplegia. MV, Mitral valve; AV, aortic
valve; CABG, coronary artery bypass grafting; CHF, congestive heart failure.
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Mfewer predictors, model 3 interpreted the data as well as
model 1. A model with only age as a predictor had an
AUC of 0.68, illustrating the dominant effect of age on the
predictability of POAF.
DISCUSSION
Logistic regression modeling is a useful tool in searching
for protective and risk factors for POAF. The results of this
method, however, are greatly influenced by the size and
characteristics of patient samples and the spectra of factors
controlled for in the analysis. The results from this study
are comparatively accurate and replicable because they arose
from analysis of a comprehensive group of risk factors based
on a large population of patients undergoing various cardiac
surgical procedures across a 20-year time period. The inci-
dences of POAF from observational studies from the 1980s
and contemporary studies are consistent with the findings of
the present study.2,10-13 The incidence of POAF oscillated
between 25% and 35% over the 20-year period of the
current study. Peaks and valleys in the incidence (in
Figure 1, eg, the incidence was 36% in 2005 and 24% in568 The Journal of Thoracic and Cardiovascular Surg1997) can be explained by the types of operations performed
during a particular year and by patient demographics, accord-
ing to the MLR results (Table 3). For example, valve proce-
dures have the highest risk of POAF (OR ¼ 1.91 for mitral
and 1.52 for aortic procedures). Among the patients in
2005, 20% had mitral and 26% had aortic valve procedures,
compared with only 6% and 14%, respectively, in 1997. The
combination of types of surgery and patient characteristics
probably explains the wide range of POAF incidences
(11%–50%) reported by other studies. From 1986 to 2005,
the annual percentage of patients with aortic or mitral valve
procedures, CHF, and hypertension increased by 17%,
16%, 14%, and 20%, respectively. Considering that these
factors were associated with a significantly higher risk of
POAF, while the average incidence of POAF remained
approximately 30%, it is reasonable to conclude that we
have made some progress over time in preventing POAF.
Increasing age remains strongly associated with POAF.
The incidence of POAF reported in previous studies has
ranged from 11% to 50%,1 possibly because of variation
in the ages of the different study groups used. In the presentery c February 2011
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Mstudy, the estimated probability of POAF was less than 20%
for patients aged less than 55 years, but increased rapidly for
patients aged 55 years and more, up to a maximum of 80%
(Figure 2), indicating a nonlinear relationship between age
and probability of having POAF. Aging has been associated
with remodeling of the atria.14 In particular, one proarrhyth-
mic change is an increase in fibrous tissue between
myocytes, which develops with age and is increased by var-
ious pathologies. This slows conduction and makes it more
heterogeneous, increasing the inducibility of atrial
fibrillation.
Among the 51 independent variables studied, 31 were as-
sociated with POAF based on univariate analysis (Table 1).
However, multivariate analysis identified 9 factors that were
associated with a higher risk of POAF: increasing age,
Caucasian race, a history of CHF, preexisting hypertension,
use of intraoperative cardioplegia or an intraaortic balloon
pump, and 3 types of cardiac surgical procedures (Table
3). Knowing the factors that are associated with a greater
risk of POAFwill help direct research and therapeutic efforts
toward the patients who need it most. For instance, an esti-
mate based on model 3 indicates that the chance of develop-
ing POAF after an aortic valve procedure for a patient aged
less than 55 years is 43%. The calculated risk would be 76%
for a mitral valve procedure involving cardioplegia per-
formed in a 72-year-old Caucasian patient with a history
of CHF and hypertension. High-risk patients could be candi-
dates for attempted drug prophylaxis or other experimental
interventions.
There has also been interest in factors associated with a de-
creased risk of POAF. For example, smoking has been cor-
related with a lower risk of POAF2 (the exact reason for this
is unknown), patients who have undergone previous cardiac
surgeries without experiencing POAF seem less likely to
have POAF after subsequent cardiac surgeries (as indicated
by the univariate analyses in this study), and pharmacologic
prophylaxis with certain drugs is believed to protect against
POAF.1,7-9,15-17 The present study did not find evidence, on
multivariate analysis, supporting an association between any
of these factors and a decreased risk of POAF.
The preoperative use of drugs, such as beta-blockers, has
been inconsistently reported to have either a protective 7,18,19
or no effect against POAF.10,13,20 None of the 13
medications in this study, when taken preoperatively, were
found to be related to the onset of POAF. There are several
possible explanations for this. First, these drugs are not
definitively known to be effective against and were not
prescribed to treat atrial fibrillation (patients with preexisting
atrial fibrillation were excluded from the study), so it is not
surprising that they were not protective against POAF.
Second, the dosages and lengths of time patients were taking
preoperative medications varied. Third, the fact that a patient
was receiving a specific drug indicated that he/she may have
had a comorbid condition requiring treatment with that drug.The Journal of Thoracic and CaIn such situations, it is difficult to separate the effects of the
comorbid condition from those of the drug on the onset of
POAF, despite the use of multivariate analysis. Fourth, it
was common for patients to be taking multiple medications,
complicating the association of any single medication’s
effect with POAF. For these reasons, studies on the effects
of pharmacologic prophylaxis for POAF should have
stringently controlled experimental designs. It should also be
pointed out that postoperative medications were not included
in our analyses because we did not have adequate
information on when these medications were given
postoperatively (eg, before or after POAF developed in
patients). It is possible that 1 or more of the 13 categories of
medications studied may be associated with a reduced
incidence of POAF when given preoperatively and
continued during the immediate postoperative period.
The discriminative power of the models, as measured by
the AUC, is only fair and suggests that the underlying causes
and mechanisms of POAF have yet to be determined.
Clearly, the strong relationship of age with POAF suggests
a need for a greater understanding of the effects of aging
on the underlying substrates for POAF. Limitations in data
availability did not allow us to test all important factors
that have reportedly been associated with POAF, for
example, the echocardiographic variables quantifying left
atrial and ventricular dimensions or function, the preopera-
tive use of amiodarone, on- versus off-pump surgery, the
type of incision, and the inflammatory response to surgery
(including postoperative pericarditis and markers such as
interleukin-6, C-reactive protein, the neutrophil/lymphocyte
ratio, and plasminogen activator inhibitor-110,20-25). These
limitations emphasize the need for a more research-
friendly centralized patient database with standardization
of commonly investigated variables and their definitions.
CONCLUSIONS
The incidence of POAF over a 20-year period has not
significantly decreased in this single-institution study.
Over this study period, the mean incidence of POAF has per-
sisted at approximately 30%. This is consistent with data
from other institutions showing that the incidence reported
in the 1980s has remained unchanged in recent observational
studies, despite the fact that numerous studies have shown
a substantial reduction in incidence after various drug thera-
pies. It is unclear why these have not translated to clinical
practice. Possibly, there is a loss of efficacy when these ther-
apies are put into a standardized clinical pathway and
applied to all patients.13 In this study, antiarrhythmic drugs,
when administered preoperatively, were not associated with
a significant reduction in POAF. Logistic regression models
using traditional preoperative and intraoperative risk factors
do not adequately predict POAF. Understanding the under-
lying pathophysiology of POAF remains elusive, and until
there is a better understanding of these mechanisms, it isrdiovascular Surgery c Volume 141, Number 2 569
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Munlikely that risk factors that adequately predict POAF will
be identified or that therapies will be developed to treat this
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